|
US5007790A
(en)
|
1989-04-11 |
1991-04-16 |
Depomed Systems, Inc. |
Sustained-release oral drug dosage form
|
|
US5582837A
(en)
|
1992-03-25 |
1996-12-10 |
Depomed, Inc. |
Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
|
|
CA2132012C
(en)
|
1992-03-25 |
2003-04-22 |
John W. Shell |
Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
|
|
AU3290397A
(en)
|
1996-06-10 |
1998-01-07 |
Depomed, Inc. |
Gastric-retentive oral controlled drug delivery system with enhanced retention properties
|
|
US5972389A
(en)
|
1996-09-19 |
1999-10-26 |
Depomed, Inc. |
Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
|
|
US6635280B2
(en)
|
1997-06-06 |
2003-10-21 |
Depomed, Inc. |
Extending the duration of drug release within the stomach during the fed mode
|
|
ATE302597T1
(de)
|
1997-06-06 |
2005-09-15 |
Depomed Inc |
Im magen verweilende orale dosierungsformen von wasserlöslichen arzneistoffen mit kontrollierter freisetzung
|
|
NZ518739A
(en)
|
1999-11-02 |
2004-12-24 |
Depomed Inc |
Pharmacological inducement of the fed mode for enhanced drug administration to the stomach
|
|
MXPA02007254A
(es)
|
2000-02-04 |
2002-12-09 |
Depomed Inc |
Forma de dosis de cubierta-y-nucleo que se aproxima a liberacion de droga de orden cero.
|
|
US6488962B1
(en)
|
2000-06-20 |
2002-12-03 |
Depomed, Inc. |
Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
|
|
US6451808B1
(en)
|
2000-10-17 |
2002-09-17 |
Depomed, Inc. |
Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists
|
|
MXPA03005696A
(es)
|
2000-12-21 |
2003-10-06 |
Glaxo Group Ltd |
Pirimidinaminas como moduladores de angiogenesis.
|
|
WO2002096404A1
(en)
|
2001-05-29 |
2002-12-05 |
Depomed Development Ltd |
Method of treating gastroesophageal reflux disease and nocturnal acid breakthrough
|
|
US6723340B2
(en)
|
2001-10-25 |
2004-04-20 |
Depomed, Inc. |
Optimal polymer mixtures for gastric retentive tablets
|
|
CA2409552A1
(en)
|
2001-10-25 |
2003-04-25 |
Depomed, Inc. |
Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
|
|
US20030091630A1
(en)
|
2001-10-25 |
2003-05-15 |
Jenny Louie-Helm |
Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
|
|
TWI312285B
(en)
|
2001-10-25 |
2009-07-21 |
Depomed Inc |
Methods of treatment using a gastric retained gabapentin dosage
|
|
JP2005508358A
(ja)
|
2001-10-25 |
2005-03-31 |
デポメド・インコーポレイテッド |
胃滞留型ロサルタン投与量を用いる治療方法
|
|
US6682759B2
(en)
|
2002-02-01 |
2004-01-27 |
Depomed, Inc. |
Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
|
|
WO2008080153A2
(en)
*
|
2006-12-22 |
2008-07-03 |
The Children's Hospital Of Philadelphia |
A novel protein kinase c therapy for the treatment of acute lung injury
|
|
WO2009014633A1
(en)
*
|
2007-07-20 |
2009-01-29 |
Trustees Of The University Of Pennsylvania |
Method of treating acute respiratory distress syndrome
|
|
EP2190429B1
(en)
|
2007-09-10 |
2016-04-20 |
Boston Biomedical, Inc. |
A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors
|
|
CA2753844A1
(en)
*
|
2008-03-05 |
2009-09-11 |
Vicus Therapeutics, Llc |
Compositions and methods for mucositis and oncology therapies
|
|
JP5823672B2
(ja)
|
2009-07-27 |
2015-11-25 |
国立大学法人 新潟大学 |
受容体シグナル伝達阻害剤を含む脳梗塞治療用医薬品組成物
|
|
US8652476B2
(en)
|
2009-07-27 |
2014-02-18 |
Niigata University |
Pharmaceutical composition for treating ischemic events
|
|
US20120107304A1
(en)
*
|
2010-04-27 |
2012-05-03 |
Boehringer Ingelheim International Gmbh |
Combination therapy in treatment of oncological and fibrotic diseases
|
|
WO2012068487A1
(en)
*
|
2010-11-18 |
2012-05-24 |
Synta Pharmaceuticals Corp. |
Preselection of subjects for therapeutic treatment with oxygen sensitive agents based on hypoxic status
|
|
MX352844B
(es)
*
|
2011-02-28 |
2017-12-11 |
Calitor Sciences Llc |
Compuestos de quinolina sustituidos y metodos de uso.
|
|
TWI557121B
(zh)
|
2011-04-21 |
2016-11-11 |
原真股份有限公司 |
新穎激酶抑制劑
|
|
WO2013066616A1
(en)
*
|
2011-10-31 |
2013-05-10 |
Glaxo Wellcome Manufacturing Pte Ltd |
Pazopanib formulation
|
|
TW201333039A
(zh)
|
2011-12-30 |
2013-08-16 |
Abbvie Inc |
雙可變域免疫球蛋白及其用途
|
|
WO2013148537A1
(en)
*
|
2012-03-29 |
2013-10-03 |
Ning Xi |
Substituted spirobicyclic compounds and methods of use
|
|
CA3280124A1
(en)
|
2013-07-31 |
2025-10-31 |
Avalyn Pharma Inc. |
Aerosol imatinib compounds and uses thereof
|
|
EP3046909A4
(en)
|
2013-09-17 |
2017-03-29 |
Pharmakea, Inc. |
Heterocyclic vinyl autotaxin inhibitor compounds
|
|
EP3052480B1
(en)
*
|
2013-09-30 |
2020-11-11 |
The Texas A & M University System |
Compositions associated with and methods of managing neutrophil movement
|
|
WO2015111947A1
(en)
*
|
2014-01-24 |
2015-07-30 |
Lg Life Sciences Ltd. |
Composition for preventing or treating acute lung injury and acute respiratory distress syndrome
|
|
WO2015164161A1
(en)
*
|
2014-04-22 |
2015-10-29 |
Calitor Sciences, Llc |
Bicylcic pyrazolone compounds and methods of use
|
|
KR20170040798A
(ko)
|
2014-08-08 |
2017-04-13 |
포사이트 비젼4, 인크. |
수용체 티로신 키나제 억제제의 안정한 가용성 제제 및 그의 제조 방법
|
|
CN110753546B
(zh)
|
2017-04-17 |
2023-11-10 |
耶鲁大学 |
治疗或预防急性肺损伤的化合物、组合物和方法
|